ATE279208T1 - Verfahren und stoffe zur behandlung des prostatakarzinomes - Google Patents

Verfahren und stoffe zur behandlung des prostatakarzinomes

Info

Publication number
ATE279208T1
ATE279208T1 AT99918940T AT99918940T ATE279208T1 AT E279208 T1 ATE279208 T1 AT E279208T1 AT 99918940 T AT99918940 T AT 99918940T AT 99918940 T AT99918940 T AT 99918940T AT E279208 T1 ATE279208 T1 AT E279208T1
Authority
AT
Austria
Prior art keywords
substances
treatment
prostate carcinoma
prostatic
carcinoma
Prior art date
Application number
AT99918940T
Other languages
English (en)
Inventor
Christopher Allen Seid
Gurpreet Singh
Original Assignee
Zonagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zonagen Inc filed Critical Zonagen Inc
Application granted granted Critical
Publication of ATE279208T1 publication Critical patent/ATE279208T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AT99918940T 1998-06-17 1999-04-30 Verfahren und stoffe zur behandlung des prostatakarzinomes ATE279208T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/099,017 US6280742B1 (en) 1998-06-17 1998-06-17 Methods and materials for the treatment of prostatic carcinoma
PCT/US1999/009592 WO1999065521A1 (en) 1998-06-17 1999-04-30 Methods and materials for the treatment of prostatic carcinoma

Publications (1)

Publication Number Publication Date
ATE279208T1 true ATE279208T1 (de) 2004-10-15

Family

ID=22272063

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99918940T ATE279208T1 (de) 1998-06-17 1999-04-30 Verfahren und stoffe zur behandlung des prostatakarzinomes

Country Status (9)

Country Link
US (1) US6280742B1 (de)
EP (1) EP1087786B1 (de)
JP (1) JP2002518345A (de)
CN (1) CN1313775A (de)
AT (1) ATE279208T1 (de)
AU (1) AU771362B2 (de)
CA (1) CA2335337A1 (de)
DE (1) DE69921130D1 (de)
WO (1) WO1999065521A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012218A1 (en) * 1999-08-16 2001-02-22 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
AU3967701A (en) * 1999-11-04 2001-05-30 Zonagen, Inc. Chitosan induced immunopotentiation
EP1315672A4 (de) 2000-06-22 2006-04-26 Rxkinetix Inc Verabreichungsträgerzusammensetzung und verfahren zur verabreichung von antigenen und anderen wirkstoffen
AU2001273034A1 (en) 2000-06-26 2002-01-08 Rxkinetix, Inc. Composition for delivery of hematopoietic growth factor
PT2829283T (pt) 2003-04-30 2017-09-08 Univ Zuerich Método para tratamento do cancro utilizando uma imunotoxina
EP1663318A4 (de) * 2003-09-08 2008-09-10 Dong Wha Pharm Ind Co Ltd Radioisotop-chitosan-komplex zur behandlung von prostatakrebs
CN1559614A (zh) * 2004-02-17 2005-01-05 浙江大学 一种多糖类纳米抗癌材料及其制备方法
WO2005080489A1 (fr) * 2004-02-23 2005-09-01 Caiteng Zhang Solution de chelate(s) metal/polymere et leurs utilisations
US20050281891A1 (en) * 2004-06-03 2005-12-22 Ecobio, Inc. Testosterone stimulant
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
RU2309740C1 (ru) 2006-08-03 2007-11-10 Исаак Григорьевич Гитлин Антиоксидант для профилактики заболеваний, связанных с окислительным стрессом, способ его получения, содержащий его гранулят и таблетированная или капсулированная форма на его основе
WO2008128330A1 (en) 2007-04-19 2008-10-30 Viventia Biotech Inc. Optimized nucleotide sequences of vb6-845 for expression of recombinant proteins
CA2700815A1 (en) * 2007-09-27 2009-04-02 Viventia Biotech Inc. Optimized nucleic acid sequences for the expression of vb4-845
EP3960215B1 (de) * 2009-12-15 2024-10-16 Incept, LLC Implantate und biologisch abbaubare bezugsmarkierungen
PL3052525T3 (pl) 2013-10-02 2020-03-31 Viventia Bio Inc. Przeciwciała anty- EpCAM i sposoby wykorzystania
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
JP6346621B2 (ja) * 2013-12-25 2018-06-20 出光興産株式会社 酒類用金属担持ゼオライト及び酒類の製造方法
CA2979400A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Dosing strategies for targeting epcam positive bladder cancer
WO2016145349A1 (en) 2015-03-12 2016-09-15 Viventia Bio Inc. Methods of treatment for epcam positive bladder cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5639022A (en) 1979-09-05 1981-04-14 Hayashibara Biochem Lab Inc Preparation of vaccine
US4446122A (en) 1979-12-28 1984-05-01 Research Corporation Purified human prostate antigen
JPS5823847B2 (ja) 1981-02-06 1983-05-18 株式会社 林原生物化学研究所 抗ヒト蛋白質抗体の製造方法
CA1261264A (en) 1984-11-29 1989-09-26 Shigeo Suzuki Immunopotentiating agents and method
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
DK0614355T3 (da) 1991-11-26 2002-03-11 Jenner Technologies Antitumorvacciner
US5516639A (en) 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
AU686660B2 (en) 1993-08-11 1998-02-12 Jenner Technologies Prostatic cancer vaccine
EP0652014A1 (de) 1993-11-10 1995-05-10 National Institute Of Immunology Behandlung von Prostatahypertrophie
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
DK0789590T3 (da) 1994-09-23 2002-11-04 Zonagen Inc Chitosaninduceret immunforstærkning

Also Published As

Publication number Publication date
AU771362B2 (en) 2004-03-18
US6280742B1 (en) 2001-08-28
CA2335337A1 (en) 1999-12-23
CN1313775A (zh) 2001-09-19
JP2002518345A (ja) 2002-06-25
EP1087786A1 (de) 2001-04-04
AU3673799A (en) 2000-01-05
EP1087786B1 (de) 2004-10-13
WO1999065521A1 (en) 1999-12-23
US20010014334A1 (en) 2001-08-16
DE69921130D1 (de) 2004-11-18

Similar Documents

Publication Publication Date Title
DE69921130D1 (de) Verfahren und stoffe zur behandlung des prostatakarzinomes
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
ATE208210T1 (de) Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
WO2003027094A3 (en) Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
DE69733611D1 (de) Verfahren und potenzierte zusammensetzung zur behandlung von migräne
PL328858A1 (en) Immunogenous peptides
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
ATE221781T1 (de) Angiostatische verbindungen und zusammensetzungen zur behandlung des glc1a glaukoms
DE69914726D1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
ATE323474T1 (de) Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
DE60228583D1 (de) Verfahren und materialien für die behandlung des testosteron-mangels bei männern
DE69915310D1 (de) Methoden zur behandlung der salzabhängigen hypertonie
ATE266031T1 (de) Verfahren und verbindungen zur behandlung proliferativer erkrankungen
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
DE60335636D1 (de) Zusammensetzungen und verfahren für die tumordiagnose und behandlung
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DK1189627T3 (da) Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
WO2002047613A3 (en) Immunogenic cancer peptides and uses thereof
DE69922364D1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion
ATE476987T1 (de) Zusammensetzungen und methoden zur behandlung von candidosen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties